Home › Health › Pharma firms’ focus on weight-loss drugs could put...
Health

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Key Points

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by...

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment

The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.

GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group.

Continue reading...
Ozempic (ORG) Mounjaro (ORG) the Access to Medicine Foundation (ORG) Novo Nordisk’s (ORG) Eli Lilly’s Mounjaro (ORG) Netherlands (LOCATION)
Originally published by The Guardian Business Read original →